Dsc Advisors, L.P. Vyne Therapeutics Inc. Transaction History

Dsc Advisors, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.12 - $4.91 $132,000 - $5.4 Million	-1,100,000 Reduced 41.2%	1,570,000 $235,000
Q1 2022 May 16, 2022	BUY	$0.5 - $1.15 $59,500 - $136,850	119,000 Added 4.66%	2,670,000 $1.74 Million
Q4 2021 Feb 14, 2022	BUY	$0.91 - $1.5 $1.32 Million - $2.18 Million	1,451,000 Added 131.91%	2,551,000 $2.6 Million
Q2 2021 Aug 16, 2021	BUY	$3.24 - $6.92 $200,410 - $428,036	61,855 Added 5.96%	1,100,000 $3.86 Million
Q1 2021 May 14, 2021	BUY	$6.34 - $12.68 $6.58 Million - $13.2 Million	1,038,145 New	1,038,145 $7.11 Million

36.5K

Ticker VYNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,005,600
Market Cap $176M
Description
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, whi...

Get notified when there are updates to the investment portfolio of Dsc Advisors, L.P., based on Form 13F filings with the SEC.

Stay updated on Dsc Advisors, L.P. with notifications on news.